Stem Cell-Derived NK Cells for Relapsed or Refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment using special immune cells (called natural killer cells) made from stem cells to fight acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if these cells can safely help control or eliminate the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have acute myeloid leukemia (AML) that is in remission, or that has come back after treatment, and you have received at least one prior treatment for it.
- You do not have an active infection.
- You have no serious heart, liver, or kidney problems.
- You have not had a severe reaction to a prior CAR-T cell treatment, and you have not received NK cell or CIK cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for patients whose acute myeloid leukemia (AML) has come back after a stem cell transplant. It uses immune cells from the original donor, combined with a low dose of a protein called IL-2, to try to fight the leukemia without causing severe side effects.
This trial tests a ready-made immune cell therapy (iNKT cells) that targets CD33 and CD70 proteins on leukemia cells. It is for people whose acute myeloid leukemia has come back or hasn't responded to treatment, offering a possible new option when standard therapies have stopped working.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This early-phase study tests whether a treatment using NK cells plus monoclonal antibodies is safe and effective for adults with relapsed or hard-to-treat acute myeloid leukemia (AML). It’s mainly looking for safety, and whether the treatment can help control the leukemia.
This trial tests whether a special immune cell infusion (NK cells) from a half-matched family donor can help keep your AML in remission after initial chemotherapy. It is meant for people who have recently achieved their first remission and are otherwise healthy enough for a second round of chemo.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.